Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

1. IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.Cancer science · 2021
   Trial
2. Incidence and Radiological Spectrum of Interstitial Lung Disease in Patients With Lung Cancer Treated With Tyrosine Kinase Inhibitors: A Single-Center Observational Study.Cureus · 2026
   Article
3. Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?Discover oncology · 2022
   Article
4. The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.Translational lung cancer research · 2021
   Review
5. Pulmonary Toxicities of Immunotherapy.Advances in experimental medicine and biology · 2021
   Article
6. Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark.Bladder cancer (Amsterdam, Netherlands) · 2021
   Article
7. Pulmonary Complications Secondary to Immune Checkpoint Inhibitors.International journal of chronic diseases · 2020
   Article
8. Immune-Related Adverse Events: Pneumonitis.Advances in experimental medicine and biology · 2020
   Review

Corrections and comments

• Comment on
  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.2017

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.